Sarah Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarah Khan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Darine Daher
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
1 shared publication - Elliot B. Tapper
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
1 shared publication - Joseph C. Ahn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Lewis Rowland Roberts
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication Marie Budev
Respiratory Institute Cleveland Clinic Cleveland Ohio USA
1 shared publication- Navreet Chowla
Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN
1 shared publication
Latest Publications
- 11 November 2026
- Published by Springer Nature in Current Hepatology Reports
- Vol. 25 (1) , 36
The Clinical, Translational and Emerging Generative Roles of Artificial Intelligence in Hepatocellular Carcinoma
- 11 November 2026
- Published by Springer Nature in Current Hepatology Reports
- Vol. 25 (1) , 36
The Clinical, Translational and Emerging Generative Roles of Artificial Intelligence in Hepatocellular Carcinoma
- 17 April 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1023-1024
Survival in de novo perihilar cholangiocarcinoma: Does transplant outperform resection?
- 17 April 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1023-1024
Survival in de novo perihilar cholangiocarcinoma: Does transplant outperform resection?
- 30 January 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 797-798
Radiating an advantage: Comparative outcomes in transarterial locoregional therapies favor radioembolization bridging for transplant candidates with hepatocellular carcinoma
- 30 January 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (6) , 797-798
Radiating an advantage: Comparative outcomes in transarterial locoregional therapies favor radioembolization bridging for transplant candidates with hepatocellular carcinoma
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Severe Bleeding From Portal Hypertension in a Young Patient With Common Variable Immunodeficiency-Associated Nodular Regenerative Hyperplasia
Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder causing hypogammaglobulinemia. Although rare, nodular regenerative hyperplasia is the most common liver complication in CVID, which can progress to noncirrhotic portal hypertension. We report a case of a young male with CVID presenting with recurrent parastomal bleeding secondary to noncirrhotic portal hypertension from CVID-associated nodular regenerative hyperplasia.
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Open AccessSevere Bleeding From Portal Hypertension in a Young Patient With Common Variable Immunodeficiency-Associated Nodular Regenerative Hyperplasia
Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder causing hypogammaglobulinemia. Although rare, nodular regenerative hyperplasia is the most common liver complication in CVID, which can progress to noncirrhotic portal hypertension. We report a case of a young male with CVID presenting with recurrent parastomal bleeding secondary to noncirrhotic portal hypertension from CVID-associated nodular regenerative hyperplasia.
- 18 July 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (2) , 277-278
Better late than resectable: Combination therapy finds its moment
- 18 July 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (2) , 277-278
Better late than resectable: Combination therapy finds its moment
- Open Access
- 14 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Tides of emotion: Hepatologists’ role in navigating depression and anxiety in liver disease
- 14 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Open AccessTides of emotion: Hepatologists’ role in navigating depression and anxiety in liver disease
- Open Access
- 8 May 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (5) , e15325
Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia
Background/aims: Direct‐acting antiviral (DAA) therapy has revolutionized solid organ transplantation by providing an opportunity to utilize organs from HCV‐viremic donors. Though transplantation of HCV‐viremic donor organs into aviremic recipients is safe in the short term, midterm data on survival and post‐transplant complications is lacking. We provide a midterm assessment of complications of lung transplantation (LT) up to 2 years post‐transplant, including patient and graft survival between HCV‐viremic transplantation (D+) and HCV‐aviremic transplantation (D‐).Methods: This is a retrospective cohort study including 500 patients from 2018 to 2022 who underwent LT at our quaternary care institution. Outcomes of patients receiving D+ grafts were compared to those receiving D‐ grafts. Recipients of HCV antibody+ but PCR‐ grafts were treated as D‐ recipients.Results: We identified 470 D‐ and 30 D+ patients meeting inclusion criteria. Crude mortality did not differ between groups (p = .43). Patient survival at years 1 and 2 did not differ between D+ and D‐ patients (p = .89, p = .87, respectively), and graft survival at years 1 and 2 did not differ between the two groups (p = .90, p = .88, respectively). No extrahepatic manifestations or fibrosing cholestatic hepatitis (FCH) occurred among D+ recipients. D+ and D‐ patients had similar rates of post‐transplant chronic lung allograft rejection (CLAD) (p = 6.7% vs. 12.8%, p = .3), acute cellular rejection (60.0% vs. 58.0%, p = .8) and antibody‐mediated rejection (16.7% vs. 14.2%, p = .7).Conclusion: There is no difference in midterm patient or graft survival between D+ and D‐LT. No extrahepatic manifestations of HCV occurred. No differences in any type of rejection including CLAD were observed, though follow‐up for CLAD was limited. These results provide additional support for the use of HCV‐viremic organs in selected recipients in LT.
- 8 May 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (5) , e15325
Open AccessHepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia
Background/aims: Direct‐acting antiviral (DAA) therapy has revolutionized solid organ transplantation by providing an opportunity to utilize organs from HCV‐viremic donors. Though transplantation of HCV‐viremic donor organs into aviremic recipients is safe in the short term, midterm data on survival and post‐transplant complications is lacking. We provide a midterm assessment of complications of lung transplantation (LT) up to 2 years post‐transplant, including patient and graft survival between HCV‐viremic transplantation (D+) and HCV‐aviremic transplantation (D‐).Methods: This is a retrospective cohort study including 500 patients from 2018 to 2022 who underwent LT at our quaternary care institution. Outcomes of patients receiving D+ grafts were compared to those receiving D‐ grafts. Recipients of HCV antibody+ but PCR‐ grafts were treated as D‐ recipients.Results: We identified 470 D‐ and 30 D+ patients meeting inclusion criteria. Crude mortality did not differ between groups (p = .43). Patient survival at years 1 and 2 did not differ between D+ and D‐ patients (p = .89, p = .87, respectively), and graft survival at years 1 and 2 did not differ between the two groups (p = .90, p = .88, respectively). No extrahepatic manifestations or fibrosing cholestatic hepatitis (FCH) occurred among D+ recipients. D+ and D‐ patients had similar rates of post‐transplant chronic lung allograft rejection (CLAD) (p = 6.7% vs. 12.8%, p = .3), acute cellular rejection (60.0% vs. 58.0%, p = .8) and antibody‐mediated rejection (16.7% vs. 14.2%, p = .7).Conclusion: There is no difference in midterm patient or graft survival between D+ and D‐LT. No extrahepatic manifestations of HCV occurred. No differences in any type of rejection including CLAD were observed, though follow‐up for CLAD was limited. These results provide additional support for the use of HCV‐viremic organs in selected recipients in LT.